Tango ends Gilead research pact, halts two programs, raises $64M to extend runway to 2028

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read

Key Changes

• high

  Gilead collaboration research term concluded in August 2025, two years early; $53.8M deferred revenue recognized in Q3 2025. No programs returned, but Q1 2026 collaboration revenue dropped to $0 from $5.4M in Q1 2025—a permanent revenue stream elimination.

  MD&A: Gilead Collaboration verify on EDGAR →
• high

  TNG260 (CoREST inhibitor) Phase 1/2 trial shut down due to limited clinical benefit; TNG961 (HBS1L degrader) paused despite reaching IND-enabling stage. Resources redirected to PRMT5 pipeline (vopimetostat, TNG456).

  MD&A: Pipeline Prioritization verify on EDGAR →
• high

  New Erasca partnership to test vopimetostat with pan-RAS molecular glue ERAS-0015 in Phase 1/2 trial starting H2 2026. Tango sponsors; Erasca supplies drug at no cost. Expands RAS-combination strategy beyond existing Revolution Medicines collaborations.

  MD&A: Erasca Collaboration verify on EDGAR →